Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
Fierce Pharma9d
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...
Healio6d
Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
AllAfrica2h
Africa: A Jab That Could Protect Against HIV for a Year At a Time, and Other Highlights From Major Conference
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
The Financial Express8d
Gilead Sciences’ annual HIV prevention injection shows promise in clinical trial, Lancet study reveals
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
Reformulation of HIV prevention drug lenacapavir makes it last for a year
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...
Investing1d
Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition
Gilead Sciences stands at a crossroads, balancing its established HIV franchise with emerging opportunities in oncology and other therapeutic areas. The success of lenacapavir in PrEP and the ...
MIT Technology Review6d
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Investing9d
Gilead reports progress in HIV prevention with lenacapavir
Gilead Sciences, Inc. (NASDAQ ... announced promising Phase 1 study results for two once-yearly formulations of lenacapavir, an investigational drug for HIV prevention, at the Conference on ...